Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment

Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers

(2022) Shanshan Lin et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules

(2022) Maria Giulia Nizi et al.   JOURNAL OF MEDICINAL CHEMISTRY

PARP Inhibitors Resistance: Mechanisms and Perspectives

(2022) Elena Giudice et al.   Cancers

Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors

(2022) Ziwei Chi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of Novel and Potent PARP/PI3K Dual Inhibitors for the Treatment of Cancer

(2021) Zhengyang Wu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer

(2021) Mei‐Kuang Chen   FEBS Journal

Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies

(2021) Zheng Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

(2021) Shuai Li et al.   BIOORGANIC CHEMISTRY

Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP

(2021) Mengzhu Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

(2021) Cheng Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2

(2021) Jiang Yu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer

(2021) Shu-Ping Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis

(2021) Jie Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

EZH2 function in immune cell development

(2020) Stephen L. Nutt et al.   BIOLOGICAL CHEMISTRY

Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors

(2020) Yongbin Tian et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors

(2020) Shuai Li et al.   BIOORGANIC CHEMISTRY

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

(2020) Sergey Karakashev et al.   CANCER CELL

PARP and PARG inhibitors in cancer treatment

(2020) Dea Slade   GENES & DEVELOPMENT

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

(2020) Ahrum Min et al.   Cancers

Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities

(2020) Shanshan Lin et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism

(2020) Lijun Wang et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target

(2020) Hao Xu et al.   CNS Neuroscience & Therapeutics

Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy

(2020) Tingting Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

(2020) Tingting Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers

(2020) Peter Makhov et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Dual-target inhibitors based on BRD4: Novel therapeutic approaches for cancer

(2020) Sitao Zhang et al.   CURRENT MEDICINAL CHEMISTRY

EZH2: a novel target for cancer treatment

(2020) Ran Duan et al.   Journal of Hematology & Oncology

Design, Synthesis, and Evaluation of New Quinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors

(2020) Chen-Xi Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

PARP inhibitor resistance: the underlying mechanisms and clinical implications

(2020) He Li et al.   Molecular Cancer

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

(2020) Xiaosa Chang et al.   Acta Pharmaceutica Sinica B

A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation

(2020) Kirsten Strømme Kierulf-Vieira et al.   Cancers

Discovery of Isoquinolinone and Naphthyridinone-based Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP1) as Anticancer Agents: Structure Activity Relationship and Preclinical Characterization

(2020) Navnath P. Karche et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers

(2020) Chaoguo Cao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Poly(ADP-ribose) polymerase inhibition: past, present and future

(2020) Nicola J. Curtin et al.   NATURE REVIEWS DRUG DISCOVERY

Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking

(2020) Ryan M. Centko et al.   ACS Omega

Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer

(2020) Junwei Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

PARP1 and PRC2 double deficiency promotes BRCA ‐proficient breast cancer growth by modification of the tumor microenvironment

(2020) A‐Yeong Yang et al.   FEBS Journal

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer

(2020) Huiyu Ren et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

(2020) Hexiang Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

HDAC6 in Diseases of Cognition and of Neurons

(2020) Patrizia LoPresti   Cells

Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

(2019) Chuanlong Guo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold

(2019) Ghada F. Elmasry et al.   BIOORGANIC CHEMISTRY

ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase β-TrCP

(2019) Tingting Guo et al.   Nature Microbiology

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

(2019) Yong Fang et al.   CANCER CELL

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors

(2019) Daniela Criscuolo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role and prospect of JMJD3 in stem cells and cancer

(2019) Xiaojiao Yin et al.   BIOMEDICINE & PHARMACOTHERAPY

Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors

(2019) Yi Zhong et al.   BIOORGANIC CHEMISTRY

Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs

(2019) Shuai Li et al.   BIOORGANIC CHEMISTRY

Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation

(2019) Ahmed T.A. Boraei et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

(2019) Shuai Wang et al.   Nature Chemical Biology

Targeted protein degradation: expanding the toolbox

(2019) Matthieu Schapira et al.   NATURE REVIEWS DRUG DISCOVERY

Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling

(2019) Nan Li et al.   Nature Communications

The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma

(2019) Samuel C. Fehling et al.   CANCER LETTERS

Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer

(2019) Fatma M. Elmenier et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy

(2019) Junwei Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Biological Functions of TNKS1 and Its Relationship with Wnt/β-Catenin Pathway in Astrocytoma

(2019) Min Chen et al.   OncoTargets and Therapy

Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development

(2018) Petra Heffeter et al.   ANTIOXIDANTS & REDOX SIGNALING

Discovery and optimization of tetrahydropyrido[4,3- d ]pyrimidine derivatives as novel ATX and EGFR dual inhibitors

(2018) Tongfei Jing et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and anticancer activities evaluation of novel 5 H -dibenzo[ b , e ]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units

(2018) Xin He et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer

(2018) Hadia Almahli et al.   BIOORGANIC CHEMISTRY

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy

(2018) Christoph Oing et al.   CANCER LETTERS

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)

(2018) Chengwei Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

(2018) Xuxing Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity

(2018) Sean W. Reilly et al.   JOURNAL OF MEDICINAL CHEMISTRY

Insights into the biogenesis, function, and regulation of ADP-ribosylation

(2018) Michael S Cohen et al.   Nature Chemical Biology

Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity

(2018) Jie Zhou et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

PARP9 is overexpressed in human breast cancer and promotes cancer cell migration

(2018) Xinghong Tang et al.   Oncology Letters

Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways

(2018) Takahiro Ito et al.   Cell Reports

The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease

(2018) Abdullah Hoter et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Identification of Amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human Non-Small Cell Lung Cancer

(2018) Xiao-Long Hu et al.   PHYTOMEDICINE

PARPs in genome stability and signal transduction: implications for cancer therapy

(2018) Luca Palazzo et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Epigenetics in neurodegenerative diseases: the role of histone deacetylases

(2018) Sorabh Sharma et al.   CNS & Neurological Disorders-Drug Targets

BRD4 and Cancer: going beyond transcriptional regulation

(2018) Benedetta Donati et al.   Molecular Cancer

Novel insight into the function of tankyrase (Review)

(2018) Mi Kim   Oncology Letters

Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy

(2017) Zigao Yuan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity

(2017) Jie Zhou et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes

(2017) Rebecca Gupte et al.   GENES & DEVELOPMENT

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

(2017) Bing Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Bromophenol Hybrids as Potential Anticancer Agents through the Ros-Mediated Apoptotic Pathway: Design, Synthesis and Biological Evaluation

(2017) Li-Jun Wang et al.   Marine Drugs

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

(2017) Calla M Olson et al.   Nature Chemical Biology

Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase-mediated antiviral response

(2017) Tatsuya Kozaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation

(2017) Harald Schuhwerk et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions

(2017) Giuliana Catara et al.   Scientific Reports

Systematic screening for skin, hair, and nail abnormalities in a large-scale knockout mouse program

(2017) John P. Sundberg et al.   PLoS One

Small-Molecule PROTACS: New Approaches to Protein Degradation

(2016) Momar Toure et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PARP inhibitor combination therapy

(2016) Amy Dréan et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Emerging roles for Polycomb proteins in cancer

(2016) Diego Pasini et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

PARP inhibitors as antitumor agents: a patent update (2013-2015)

(2016) Zigao Yuan et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population

(2016) Min Kyung Lee et al.   Genetic Testing and Molecular Biomarkers

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes

(2016) Dong Wang et al.   GYNECOLOGIC ONCOLOGY

PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation

(2016) Hiroshi Iwata et al.   Nature Communications

PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer

(2016) Guangying Qi et al.   Oncotarget

Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells

(2016) Yizhou Yao et al.   Genes

Spermatid Head Elongation with Normal Nuclear Shaping Requires ADP-Ribosyltransferase PARP11 (ARTD11) in Mice1

(2015) Mirella L. Meyer-Ficca et al.   BIOLOGY OF REPRODUCTION

Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer

(2015) Qihua Zhu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors

(2015) Haiping Yao et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents

(2015) Chunmei Gao et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma

(2015) J. L. Pokorny et al.   CLINICAL CANCER RESEARCH

Redox-active biflavonoids from Garcinia brasiliensis as inhibitors of neutrophil oxidative burst and human erythrocyte membrane damage

(2015) Phanuel Saroni Arwa et al.   JOURNAL OF ETHNOPHARMACOLOGY

Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

(2015) Bing Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

PARP inhibitors: A new era of targeted therapy

(2015) Shifalika Tangutoori et al.   MATURITAS

RNA Regulation by Poly(ADP-Ribose) Polymerases

(2015) Florian J. Bock et al.   MOLECULAR CELL

PARPs and ADP-Ribosylation: 50 Years … and Counting

(2015) W. Lee Kraus   MOLECULAR CELL

PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain

(2015) Jennine M. Dawicki-McKenna et al.   MOLECULAR CELL

Cytotoxic flavonoids and other constituents from the stem bark ofOchna schweinfurthiana

(2015) Joseph T. Ndongo et al.   NATURAL PRODUCT RESEARCH

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-inflammatory activity of flavonoids from Chrozophora tinctoria

(2015) Hossam M. Abdallah et al.   Phytochemistry Letters

Phthalimide conjugation as a strategy for in vivo target protein degradation

(2015) G. E. Winter et al.   SCIENCE

Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer

(2015) Tanya Todorova et al.   TRENDS IN MOLECULAR MEDICINE

PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation

(2015) Valeria Iansante et al.   Nature Communications

Glioma

(2015) Michael Weller et al.   Nature Reviews Disease Primers

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

(2014) Panagiotis A. Konstantinopoulos et al.   GYNECOLOGIC ONCOLOGY

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

(2014) Lei Zhang et al.   MEDICINAL RESEARCH REVIEWS

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells

(2014) Samia B Bachmann et al.   Molecular Cancer

Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP

(2014) O. S. Chao et al.   MOLECULAR CANCER RESEARCH

ADP-Ribosylation: Activation, Recognition, and Removal

(2014) Nan Li et al.   MOLECULES AND CELLS

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript

(2014) Tanya Todorova et al.   Nature Communications

Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone

(2014) Mika Aoyagi-Scharber et al.   Acta Crystallographica Section F-Structural Biology Communications

Caspase-dependent cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic function

(2013) Nicolas Herzog et al.   FEBS Journal

Interferon-Stimulated Poly(ADP-Ribose) Polymerases Are Potent Inhibitors of Cellular Translation and Virus Replication

(2013) S. Atasheva et al.   JOURNAL OF VIROLOGY

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

(2013) Nicola J. Curtin et al.   MOLECULAR ASPECTS OF MEDICINE

A systematic analysis of the PARP protein family identifies new functions critical for cell physiology

(2013) Sejal Vyas et al.   Nature Communications

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?

(2013) Amanda Swindall et al.   Cancers

Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors

(2012) Maja T. Tomicic et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development

(2012) HANDAN TUNCEL et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1α-mediated unfolded protein response

(2012) Miri Jwa et al.   NATURE CELL BIOLOGY

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

(2012) Bryan A. Gibson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Topoisomerase I poisoning results in PARP-mediated replication fork reversal

(2012) Arnab Ray Chaudhuri et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation

(2012) Laura MacPherson et al.   NUCLEIC ACIDS RESEARCH

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma

(2012) A Barbarulo et al.   ONCOGENE

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

(2012) S. R. Stecklein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation

(2011) G-H Ha et al.   CELL DEATH AND DIFFERENTIATION

Bromophenols in Marine Algae and Their Bioactivities

(2011) Ming Liu et al.   Marine Drugs

Poly(ADP-Ribose) Regulates Stress Responses and MicroRNA Activity in the Cytoplasm

(2011) Anthony K.L. Leung et al.   MOLECULAR CELL

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

(2011) C. Boehler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

DNA repair and personalized breast cancer therapy

(2010) Shu-Xia Li et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic

(2010) Dana V. Ferraris   JOURNAL OF MEDICINAL CHEMISTRY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Nuclear phosphoinositide 3-kinase   controls double-strand break DNA repair

(2010) A. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry

(2010) Maxim Isabelle et al.   Proteome Science

Toward a unified nomenclature for mammalian ADP-ribosyltransferases

(2010) Michael O. Hottiger et al.   TRENDS IN BIOCHEMICAL SCIENCES

Proteasome-dependent Processing of Topoisomerase I-DNA Adducts into DNA Double Strand Breaks at Arrested Replication Forks

(2009) Chao-Po Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

(2009) F. Zhang et al.   MOLECULAR CANCER RESEARCH

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

(2009) M. J. Clarke et al.   MOLECULAR CANCER THERAPEUTICS

The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series

(2008) Antoinette Hakmé et al.   EMBO REPORTS

Identification of lysines 36 and 37 of PARP-2 as targets for acetylation and auto-ADP-ribosylation

(2008) Sandra S. Haenni et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

(2008) Keith A. Menear et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies Transcriptional Outcomes

(2008) R. Krishnakumar et al.   SCIENCE

Toward specific functions of poly(ADP-ribose) polymerase-2

(2008) José Yélamos et al.   TRENDS IN MOLECULAR MEDICINE

Tankyrase function at telomeres, spindle poles, and beyond

(2007) Susan J. Hsiao et al.   BIOCHIMIE